Bertrand Duvillié1,2,3,4,5*
Ralf Jockers6*- 1Department of Signaling, Radiobiology and Cancer, Institut Curie, Orsay, France
- 2Inserm U1021, Centre Universitaire, Orsay, France
- 3CNRS UMR 3347, Centre Universitaire, Orsay, France
- 4Université Paris-Saclay, Orsay, France
- 5PSL Research University, Paris, France
- 6Université Paris Cité, Institut Cochin, Inserm, CNRS, Paris, France
Editorial on the Research Topic
Hypoxia, oxidative stress, and endocrine cancers
The Research Topic “hypoxia, oxidative stress and endocrine cancers” aims to present innovative strategies to investigate the role of hypoxia and oxidative stress in endocrine cancers. Such analysis of the hypoxic environment will allow an improved understanding of the contribution of the cellular and molecular signaling pathways associated with tumor initiation, progression, and metastasis, and the subsequent knowledge will help to improve cancer treatments such as chemotherapy and radiotherapy.
Oxygen pressure (pO2) is involved in many important biological functions, including metabolism, proliferation, angiogenesis, and apoptosis, while dysregulation of oxygen metabolism has been implicated in a number of cancers. Research has indicated that the pO2 varies widely between different tissues, with many being hypoxic, with a concentration range from 6 to 34 mmHg (1% to 5% O2) (1). Indeed, in the atmosphere and upper airways, the oxygen level is 160 mmHg (21% O2) and 150 mmHg (19.7% O2), respectively (2). The pO2 of the arterial blood is generally 95 mmHg (12.5% O2), decreasing to 40 mmHg (5.2% O2) in venous blood. Conversely, in the mouse thymus, the oxygen value was estimated at only 7.6 mmHg (1% O2) (3). Semenza et al. indicated that the hypoxia-inducible factors (HIFs) play a central role in the signaling pathways involved in cancer progression. The HIF1α protein is generally expressed in tissues when pO2 is below 34 mmHg (5% O2). HIF transcription factors control the expression of thousands of genes, regulating crucial mechanisms, including angiogenesis, cancer stem cell specification, cell motility, epithelia-mesenchymal transition, extra-cellular matrix remodeling, glucose and lipid metabolism, immune evasion, invasion, and metastasis (4). The level of HIF protein expression is tightly regulated by both oxygen-dependent and independent signals to ensure a functional equilibrium.
An example of the concentration effect of HIF1α can be seen in the study of pancreatic beta cell function (5). Indeed, HIF1α is present at very low levels under physiological conditions in both mouse and human beta-cells. A beta-cell specific HIF1α disruption in mice leads to glucose intolerance and beta-cell dysfunction (6). Interestingly, the gain of function of HIF1α, induced by the deletion of the tumor suppressor VHL, leads to defective beta-cell differentiation (7) and altered beta-cell function (8–10).
This phenotype is similar to that caused by the loss of HIF1α function. Thus, this counterintuitive observation highlights the importance of HIF1α dosage for endocrine function. Moreover, patients with a mutation in VHL develop Von Hippel Lindau disease, with some patients developing cystic serous adenoma, and/or pancreatic neuroendocrine tumors (11).
In this Research Topic, Watts et al. present an overview of the recent finding on the central role of the HIF axis and its inhibitors, the Prolyl Hydroxylase Domain proteins (PHDs), in endocrine tumors. The relationship between oxygen tension and reactive oxygen species (ROS) has previously been established (12) and Cui et al. identified eleven mitochondrial genes related to oxidative stress that are associated with the progression of pancreatic cancer and pancreatic neuroendocrine tumors.
Women’s cancers are also frequently concerned by endocrine tumors and their hypoxic microenvironment. In a recent study, Pereira et al. presented an overview on the role of hypoxia in ovarian cancer, and its effects on the immune environment. Importantly, they analyzed the impact on chemoresistance and discussed the future possibilities of personalized therapies. Chen et al. further established a model based on hypoxia-related gene expression to predict prognosis in endometrial cancer, another female-specific tumor. This model is based on a genetic signature of 4 genes: ANXA2, AKAP12, NR3C1, and GPI. Finally, Quinting et al. analyzed the role of myoglobin, an oxygen-binding protein that exhibits a scavenging capacity for reactive oxygen and nitrogen species, in breast cancer. Their results strongly suggest that myoglobin supports the survival of breast cancer cells due to its scavenging properties.
The role of oxidative stress in cancer has also been extended to other types of tumors. For example, Dong et al. showed that a novel molecular classification incorporating oxidative stress and metabolism-related genes could be used for prognosis prediction and personalized medicine in stomach adenocarcinoma.
Finally, in the last part of this Research Topic, the application of hypoxia studies to cancer therapy is proposed. Indeed, it was shown that oxygen tension can considerably influence radiotherapy efficiency, with hypoxia being one of the most important causes of radioresistance. Moreover, hypoxia is associated with a poor prognosis after radiotherapy. Rakotomalala et al. analyzed the different mechanisms by which hypoxia may influence the efficacy of radiotherapy in solid tumors. In particular, they detail the 6 parameters considered in the field of radiotherapy, known as the “6Rs of radiation biology”: Radiosensitivity, Repair, Repopulation, Redistribution, Reoxygenation, and Reactivation of anti-tumor immune response. This review presents innovative data concerning the effects of hypoxia during radiotherapy, and describes the results of recent clinical trials. To return to the main focus of this Research Topic, endocrine tumors, the authors analyze these effects in the case of anaplastic thyroid carcinoma.
Overall, this Research Topic presents new concepts on the role of hypoxia and oxidative stress in endocrine cancer, while also providing new tools and directions to classify the patients and to delineate the molecular mechanisms for a future optimization of the treatments and the development of a personalized medicine.
Author contributions
BD: Conceptualization, Investigation, Validation, Writing – original draft, Writing – review & editing. RJ: Validation, Writing – original draft, Writing – review & editing.
Funding
BD received support from Société Francophone du Diabète (Grant number 26866) and by Gefluc (Les entreprises contre le cancer, Grant number 25449).
Acknowledgments
We thank Eleanor Hawkins and Dave NG for proofreading our manuscript.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Abbreviations
AKAP12, A-Kinase Anchoring Protein 12; ANXA2, Annexin A2; GPI, Glucose-6-Phosphate Isomerase; HIFs, Hypoxia Inducible Factors; HIF1α, Hypoxia Inducible Factors 1 alpha; mmHg, Millimetre of Mercury; NR3C1, Nuclear Receptor Subfamily 3 Group C Member 1; PHDs, Prolyl Hydroxylase Domain proteins; pO2, Partial Pressure of Oxygen; VHL, von Hippel-Lindau tumor suppressor.
References
1. Sullivan M, Galea P, Latif S. What is the appropriate oxygen tension for in vitro culture? Mol Hum Reprod (2006) 12:653. doi: 10.1093/molehr/gal081
2. Carreau A, Hafny-Rahbi BE, Matejuk A, Grillon C, Kieda C. Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia. J Cell Mol Med (2011) 15:1239–53. doi: 10.1111/j.1582-4934.2011.01258.x
3. Braun RD, Lanzen JL, Snyder SA, Dewhirst MW. Comparison of tumor and normal tissue oxygen tension measurements using OxyLite or microelectrodes in rodents. Am J Physiol Heart Circ Physiol (2001) 280:H2533–44. doi: 10.1152/ajpheart.2001.280.6.H2533
4. Wicks EE, Semenza GL. Hypoxia-inducible factors: cancer progression and clinical translation. J Clin Invest (2022) 132:e159839. doi: 10.1172/JCI159839
5. Duvillié B. Vascularization of the pancreas: an evolving role from embryogenesis to adulthood. Diabetes (2023) 62:4004–5. doi: 10.2337/db13-1421
6. Cheng K, Ho K, Stokes R, Scott C, Lau SM, Hawthorne WJ, et al. Hypoxia-inducible factor-1α regulates β cell function in mouse and human islets. J Clin Invest (2010) 120:2171–2183. doi: 10.1172/JCI35846
7. Soggia A, Ramond C, Akiyama H, Scharfmann R, Duvillie B. von Hippel–Lindau gene disruption in mouse pancreatic progenitors and its consequences on endocrine differentiation in vivo: importance of HIF1-α and VEGF-A upregulation. Diabetologia (2014) 57:2348–56. doi: 10.1007/s00125-014-3365-y
8. Cantley J, Selman C, Shukla D, Abramov AY, Forstreuter F, Esteban MA, et al. Deletion of the von Hippel–Lindau gene in pancreatic β cells impairs glucose homeostasis in mice. J Clin Invest (2008) 119(1):125–35. doi: 10.1172/JCI26934
9. Puri S, Cano DA, Hebrok M. A role for von Hippel-Lindau protein in pancreatic β-Cell function. Diabetes (2009) 58:433–41. doi: 10.2337/db08-0749
10. Zehetner J, Danzer C, Collins S, Eckhardt K, Gerber PA, Ballschmieter P, et al. pVHL is a regulator of glucose metabolism and insulin secretion in pancreatic β cells. Genes Dev (2008) 22:3135–46. doi: 10.1101/gad.496908
11. Hammel PR, Vilgrain V, Terris B, Penfornis A, Sauvanet A, Correas J, et al. Pancreatic involvement in von Hippel–Lindau disease. Gastroenterology (2000) 119:1087–95. doi: 10.1053/gast.2000.18143
Keywords: hypoxia, oxidative stress, endocrine tumors, radiotherapy, HIF - 1α
Citation: Duvillié B and Jockers R (2023) Editorial: Hypoxia, oxidative stress, and endocrine cancers. Front. Endocrinol. 14:1268268. doi: 10.3389/fendo.2023.1268268
Received: 27 July 2023; Accepted: 29 September 2023;
Published: 16 October 2023.
Edited and Reviewed by:
Joanna K. Filipowska, City of Hope National Medical Center, United StatesCopyright © 2023 Duvillié and Jockers. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Bertrand Duvillié, bertrand.duvillie@curie.fr; Ralf Jockers, ralf.jockers@inserm.fr